Loading...
XKRX
185750
Market cap789mUSD
May 27, Last price  
82,000.00KRW
1D
-0.36%
1Q
-0.49%
Jan 2017
-13.49%
IPO
12.48%
Name

Chong Kun Dang Pharmaceutical Corp

Chart & Performance

D1W1MN
P/E
9.91
P/S
0.68
EPS
8,278.09
Div Yield, %
—
Shrs. gr., 5y
1.19%
Rev. gr., 5y
8.01%
Revenues
1.59t
-4.97%
86,318,151,860544,129,759,250592,493,473,520831,985,529,730884,362,807,620956,218,889,2801,079,337,661,9901,303,005,524,3901,343,559,362,9101,488,344,728,6401,669,404,438,7601,586,430,795,630
Net income
109.07b
-48.68%
4,416,973,92035,153,740,950-6,772,741,42040,946,103,41053,807,202,37042,398,534,69053,881,645,93091,632,758,68042,720,380,72080,953,361,430212,521,171,442109,072,842,040
CFO
64.29b
-79.79%
9,959,708,95064,590,673,0807,271,990,76057,786,120,79081,672,834,51042,627,762,18077,290,596,980104,323,716,84012,903,868,10067,734,467,550318,159,906,41064,289,067,640
Dividend
Dec 27, 20231047.618 KRW/sh
Earnings
Aug 12, 2025

Profile

Chong Kun Dang pharmaceutical Corp. engages in the manufacturing, marketing, and selling of medicines in South Korea and internationally. It provides prescription drugs for anti-hypertension, anti-hyperlipidemia, and anti-diabetics; over-the-counter drugs, such as Penzal, Prefemine, and Modcol, as well as consumer health products, such as insecticides, hair dye, etc.; and healthcare supplements with preventive benefits. The company also exports its products. Chong Kun Dang pharmaceutical Corp. was founded in 1941 and is headquartered in Seoul, South Korea.
URL
https://www.ckdpharm.com/
IPO date
Dec 06, 2013
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,586,430,796
-4.97%
1,669,404,439
12.17%
1,488,344,729
10.78%
Cost of revenue
1,337,695,865
1,278,813,300
1,238,481,271
Unusual Expense (Income)
NOPBT
248,734,931
390,591,139
249,863,458
NOPBT Margin
15.68%
23.40%
16.79%
Operating Taxes
(9,432,817)
27,995,661
17,187,287
Tax Rate
7.17%
6.88%
NOPAT
258,167,748
362,595,478
232,676,171
Net income
109,072,842
-48.68%
212,521,171
162.52%
80,953,361
89.50%
Dividends
(13,331,034)
(11,608,529)
(11,238,797)
Dividend yield
1.13%
0.70%
1.17%
Proceeds from repurchase of equity
(16,007,713)
(6,024,992)
(1,888,365)
BB yield
1.35%
0.36%
0.20%
Debt
Debt current
69,471,834
184,767,366
124,445,495
Long-term debt
124,384,016
43,061,468
112,986,798
Deferred revenue
3,236,745
1,484,754
6,438,253
Other long-term liabilities
71,910,959
38,846,152
11,650,103
Net debt
(76,649,241)
(178,380,083)
76,005,642
Cash flow
Cash from operating activities
64,289,068
318,159,906
67,734,468
CAPEX
(38,474,001)
(68,806,048)
(53,064,680)
Cash from investing activities
3,730,766
(171,312,904)
(65,380,323)
Cash from financing activities
(63,111,548)
(43,699,980)
(16,339,806)
FCF
172,665,744
364,848,773
174,578,552
Balance
Cash
302,170,759
365,065,295
155,861,194
Long term investments
(31,665,668)
41,143,622
5,565,457
Excess cash
191,183,551
322,738,695
87,009,415
Stockholders' equity
706,781,788
249,464,234
681,943,085
Invested Capital
966,085,426
826,265,721
759,079,384
ROIC
28.81%
45.74%
32.02%
ROCE
21.45%
36.31%
29.53%
EV
Common stock shares outstanding
13,291
12,723
12,249
Price
89,000.00
-32.01%
130,900.00
67.41%
78,190.40
-22.34%
Market cap
1,182,899,000
-28.97%
1,665,397,110
73.88%
957,783,844
-23.53%
EV
1,108,658,823
1,486,957,701
1,032,685,219
EBITDA
288,507,255
427,621,015
283,461,120
EV/EBITDA
3.84
3.48
3.64
Interest
8,318,977
9,270,969
6,846,931
Interest/NOPBT
3.34%
2.37%
2.74%